Figure 2.

Patient disposition. HC, hydroxycarbamide. *Arterial occlusive disease, blurred vision, diarrhoea, fatigue, increased platelet count, muscular weakness, musculoskeletal and connective tissue disorders, pyrexia, unstable angina, upper abdominal pain, and urinary tract pain; >1 adverse event could be the cause of discontinuation in a given patient. ^†Deep vein thrombosis. ^‡Data cut‐off for this analysis occurred when the last patient completed the Week 16 visit. Patients were still in the blinded phase at data cut‐off if the unblinding date was missing or occurred after the cut‐off date.